4D Molecular Therapeutics Inc (FDMT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at 4D Molecular Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.10 $ — 61% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 40.0%
- Exp. sales growth 3Y > 5% -54.6%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -54.6%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -27.7%
- ROCE > 15% -30.5%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 200.8% passed
- More than 10% revenue growth is expected for the coming year 50.9% passed
- Share count grows by less than 3% a year 21.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 230,066.0% passed
- Gross margin at 40% or higher and without meaningful erosion 91.1% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 381 m net cash passed
- Operating cash flow covers the profits of the last three years 82 m failed
- Return on capital at 15% or higher, or up versus two years ago -30.5% failed
- Insiders hold at least 10% or are net buyers 3.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 188.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.95 | -4.27 – -3.04 | 12 | -63.4% | 10 |
| 12/31/2027 | -3.83 | -4.63 – -1.55 | 18 | 3.2% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.04 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.92 | – | 0 | – | -4,967,100.00 | -46 | -47 |
| 2025: Q1 | -0.86 | – | 0 | -50.00 | -342,657.10 | -48 | -48 |
| 2025: Q2 | -0.98 | – | 0 | 200.00 | -364,386.70 | -43 | -43 |
| 2025: Q3 | -1.01 | – | 0 | 2,900.00 | -63,195.60 | -47 | -46 |
| 2025: Q4 | 0.33 | – | 85 | 8,508,900.00 | 22.80 | 29 | 28 |
| 2026: Q1 | -1.01 | – | 3 | 21,664.30 | -2,256.60 | -68 | -68 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 6 | -11 | -11 | -0.76 | 8 | -20 | 27 |
| 2018 | 14 | -10 | -10 | -0.76 | -16 | -28 | 97 |
| 2019 | 7 | -51 | -49 | -1.86 | -37 | -73 | 58 |
| 2020 | 14 | -57 | -57 | -2.12 | -51 | 256 | 288 |
| 2021 | 18 | -71 | -68 | -2.46 | -69 | 319 | 353 |
| 2022 | 3 | -110 | -101 | -3.12 | -87 | 231 | 262 |
| 2023 | 21 | -113 | -101 | -2.58 | -76 | 308 | 340 |
| 2024 | 0 | -188 | -161 | -2.98 | -135 | 511 | 560 |
| 2025 | 85 | -160 | -140 | -2.42 | -109 | 506 | 567 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
4D Molecular Therapeutics, Inc., ein Biotechnologieunternehmen in später Phase, beschäftigt sich mit der Entwicklung von adeno-assoziierten Virusvektoren aus seiner proprietären synthetischen Vektor-Entdeckungsplattform Therapeutic Vector Evolution in den Niederlanden und den USA.
| Employees | 196 |
|---|---|
| Headquarters | EmeryVille, CA |
| Address | 5858 Horton Street, 94608 EmeryVille, United States |
| Phone | 510 505 2680 |
| Website | 4dmoleculartherapeutics.com |
| IPO Date | 11. Dec 2020 |
| ISIN | US35104E1001 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John F. Milligan Ph.D. | Executive Chairman | 1961 |
| David H. Kirn M.D. | Co-Founder, President, CEO & Director | 1962 |
| Kristian Humer M.B.A. | CFO and Principal Financial & Accounting Officer | 1976 |
| Fariborz Kamal Ph.D. | Chief Technical Advisor | 1963 |
| Theresa Janke | Co-Founder & Chief of Staff | 1975 |
| Julian Pei | Head of Investor Relations & Corporate Finance | – |
| Katy Barglow Ph.D. | Chief Technical Officer | – |
| Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1972 |
| An Song Ph.D. | Chief Translational Medicine Advisor | – |
| Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Advisor | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Kirn David | See Remarks | Sell | 442 | 12.84 | 5,673 |
| 10. Jul 2026 | Kirn David | See Remarks | Sell | 15,283 | 12.01 | 183,560 |
| 9. Jul 2026 | Kirn David | See Remarks | Sell | 42,608 | 12.87 | 548,177 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.